Taselisib showed greater activity among the 152 patients who had PIK3CA mutant cancer cells detected at baseline, with 56.2% showing an ORR compared to 38% of patients who received placebo ([OR] 2.03, 95%CI 1.06–3.88, p = 0.033) [84]. This evidence concerns the gene PIK3CA and cancer.